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Objective: To assess effects of lisdexamfetamine dimesylate (LDX) and mixed amphetamine 
salts extended release (MAS XR) on symptom improvement in children with attention-deficit/
hyperactivity disorder (ADHD).
Methods: Post hoc analysis of a randomized, double-blind, placebo-controlled, crossover 
analog-classroom environment was conducted. The primary efficacy outcome was the deportment 
subscale of the Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP-D) rating scale. The 
secondary efficacy outcome was the investigator-rated Clinical Global Impressions-Improvement 
(CGI-I), a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), which 
assesses improvement over time from baseline. McNemar test was used to compare participants’ 
responses to LDX and MAS XR on CGI-I scores dichotomized into 1 (very much improved) 
vs all other response scores (2 to 7) in a 2 × 2 table.
Results: Fifty-two children (aged 6 to 12 years) were enrolled, titrated, and randomized; 
50   completed the study. Investigators rated 74% of LDX participants as either very much 
improved or much improved on the CGI-I scale relative to 72% of MAS XR participants 
and 18% of placebo participants. Of the 50 children who completed the study, 32% of LDX 
participants were very much improved vs 16% of MAS XR, and 2% of placebo participants 
relative to baseline. McNemar test indicated that 10 participants were very much improved with 
LDX, but not MAS XR; 2 participants were very much improved with MAS XR, but not LDX; 
6 participants were very much improved with both, while 32 were not very much improved 
with either. Analysis showed that LDX had a significantly higher number of children with a 
very much improved score on the CGI-I than MAS XR (P = 0.0386).
Conclusion: Treatment of children with LDX resulted in a higher number of participants with 
a very much improved score on the CGI-I than treatment with MAS XR or placebo.
Keywords: lisdexamfetamine dimesylate, LDX, Vyvanse, mixed amphetamine salts, extended 
release, ADHD, CGI-I
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common psychi-
atric disorders of childhood and is estimated to affect approximately 5.3% of children 
and adolescents worldwide.1 According to the Diagnostic and Statistical Manual of Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Mental Disorders (DSM-IV-TR) criteria for ADHD, the dis-
order is generally characterized by inattention, difficulty in 
performing tasks, hyperactivity, and impulsivity to a degree 
that is inconsistent with the developmental level for that age.2 
Stimulants are considered a first-line choice of treatment for 
patients with ADHD, and the short- and long-term efficacy 
of these medications in improving ADHD symptoms is well 
established.3 Since immediate-release stimulant formulations 
need multiple dosing regimens per day, long-acting forms 
have been developed.3
Lisdexamfetamine dimesylate (LDX; Vyvanse®, Shire 
US Inc.) is the first long-acting prodrug stimulant, which is 
therapeutically inactive, and is indicated for the treatment 
of ADHD in children 6 to 12 years of age, adolescents 13 to 
17 years, and in adults. After oral ingestion, LDX is converted 
to l-lysine and active d-amphetamine. While a small amount 
of LDX is hydrolyzed to d-amphetamine in the gastrointesti-
nal tract, the conversion of LDX into active d-amphetamine 
occurs primarily in the blood.4 There was low interpatient 
variability of pharmacokinetic parameters in a clinical trial 
of pediatric participants with ADHD, possibly due to the 
biological rather than mechanical delivery of LDX.5
LDX has demonstrated safety consistent with long-
acting stimulant use and an extended duration of efficacy as 
assessed in various trials. In a randomized, controlled trial 
in children with ADHD, LDX was effective in controlling 
symptoms throughout the day, up to 6 pm, as measured by 
parent ratings using Conners’ Parent Rating Scale-Revised 
(CPRS-R) scores6 after a median dosing time between 
7:30 am and 8:00 am.7 Efficacy was also demonstrated by 
clinician measures such as Clinical Global Impressions (CGI) 
scale scores and ADHD Rating Scale IV (ADHD-RS-IV) 
total scores.6 The most common significant adverse events 
(AEs) included weight loss, decreased appetite, dizziness, 
insomnia, and irritability, which are typical of stimulants 
and no serious AEs were observed. All AEs were mild or 
moderate in intensity and subsided with time.6
A randomized, double-blind, placebo- and active-
  controlled study in an analog classroom demonstrated that 
LDX treatment in children was effective compared with 
placebo, beginning 2 hours after dosing, and continuing 
through the last time point assessed (12 hours postdose).5 
This study examined treatment with LDX, mixed amphet-
amine salts extended release (MAS XR), and placebo, in a 
crossover fashion.
Efficacy was assessed using the primary efficacy mea-
sure of Swanson, Kotkin, Agler, M-Flynn, and Pelham 
Deportment (SKAMP-D) scores and secondary measures 
of SKAMP Attention (SKAMP-A), Permanent Product 
  Measure of Performance-Attention (PERMP-A), PERMP-
Correct (PERMP-C), and CGI-Improvement (CGI-I), in 
which LDX and MAS XR were significantly more effective 
relative to placebo, with no differences between the active 
treatments in the results of the primary efficacy analysis.5
LDX was also effective from 1.5 to 13 hours postdose in 
a later randomized controlled trial in children in a laboratory 
classroom study.8 AEs were consistent with other pediatric 
studies of LDX.
Although general efficacy of stimulant medications 
including LDX and MAS XR has been well characterized, 
there was a desire to further understand the proportion of 
significant responders to medication treatment. Medication 
trials of ADHD frequently report a 30% improvement in 
ADHD symptoms, and/or a response designated as improved 
on the CGI-I scale, which is a score of 1 or 2. We are unaware 
of studies that have focused on the more stringent definition 
of very much improved, or CGI-I rating score of 1. A search 
of the available literature did not identify other studies that 
reported participant data for ratings of very much improved 
(CGI-I rating score of 1) alone as an improvement measure. 
Since an inspection of the relative proportions of participants 
by CGI-I category suggested differences between the active 
treatments, we conducted a post hoc analysis of the earlier 
analog classroom study by Biederman et al to compare effi-
cacy differences in the extent of global symptom improve-
ment of very much improved in participants with ADHD, 
who responded to LDX and MAS XR treatment vs placebo 
in accordance with the CGI-I assessment scale, a clinician-
rated measure of improvement.5
Methods
study design
Children aged 6 to 12 years with a primary diagnosis of 
ADHD of the combined or predominantly hyperactive-
impulsive subtypes, as defined by DSM-IV-TR criteria, were 
eligible for enrollment in this randomized, double-blind, 
placebo-controlled, analog classroom study. The study design 
as illustrated in Figure 1 comprised 3 treatment periods: 
1-week screening; 3-week open-label titration to optimal 
MAS XR dose (10, 20, or 30 mg/day); 3-week randomized, 
double-blind (ie, participants and investigators) treatment 
crossover periods with optimum dose of MAS XR, LDX 
dose approximately equivalent to the optimized MAS 
XR dose, and placebo. Final selection of optimal MAS XR Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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dose and randomization to order of double-blind treatment 
sequence occurred during visit 5 along with practice analog 
  classroom sessions. Blinding was ensured through use of 
matching capsule formulations and the delivery of prepack-
aged individual drug kits based on randomization numbers. 
No unblinding or breaking of treatment codes occurred dur-
ing the study. Participants were evaluated in the laboratory 
school on the last day of each week of the double-blind period. 
All study activities were performed in accordance with the 
principles of the International Conference on Harmonisation 
Good Clinical Practice, 18th World Medical Assembly 
(Helsinki 1964), and amendments of the 29th (Tokyo 1975), 
the 35th (Venice 1983), the 41st (Hong Kong 1989), and the 
48th (South Africa 1996) World Medical Assemblies.
The primary efficacy measure was SKAMP-D, which 
measures classroom symptoms of ADHD using an indepen-
dent observer. It is scored on a 7-point impairment scale from 
0 to 6, with higher scores indicative of more severe   symptoms. 
SKAMP-D results were reported as the least squares (LS) 
mean per item score. The secondary efficacy measures 
included the SKAMP-A, PERMP-A and PERMP-C, and the 
CGI-I scores. PERMP is a validated 10-minute math test to 
evaluate response to stimulant medications.
The CGI scale is an investigator-rated evaluation of a sub-
ject’s improvement over time by rating change in   symptoms.9 
Investigators were thoroughly trained on administration 
and evaluation based on the CGI ratings. Each subject was 
assessed at baseline on the CGI-Severity (CGI-S) 7-point 
scale, with severity of ADHD symptoms rated from 1 (no 
symptoms) to 7 (very severe symptoms). At each crossover 
visit, subject improvement in ADHD symptoms relative to 
baseline was determined by the investigator on the CGI-I 
scale, a 7-point scale ranging from 1 (very much improved) 
to 7 (very much worse).
Analog classroom environment
Each classroom day (weeks 6, 7, 8) lasted 13 hours 
(approximately 6:30 am to 7:45 pm). Participants took the 
randomized treatment each morning at home for the first 
6 days and then the day-7 dose was given during the analog 
classroom visit. Thirty-minute classroom sessions, including 
the practice visit, were scheduled at approximately 1, 2, 3, 
4.5, 6, 8, 10, and 12 hours after the morning study dose was 
administered.
safety assessments
AEs were collected throughout the study and at each study 
visit. A 30-day telephone follow-up screened for serious 
AEs. Vital signs were obtained at all clinic visits.   Laboratory 
parameters and physical examination information were 
collected on all participants at screening and at final study 
visit. Electrocardiogram (ECG) measurements were taken 
at screening, practice visit (week 5), double-blind treatment 
visits (weeks 6 to 8), and final study visit.
statistics
A mixed-effects model of analysis of variance was conducted 
to assess mean CGI-I scores for the intention-to-treat (ITT) 
population. Given a significant overall treatment effect 
(P , 0.05), pairwise comparisons of LS means between 
individual treatments were conducted using a t test. No multi-
plicity adjustments were made on subgroup statistical 
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Figure 1 schematic diagram of study design.a
Notes: aParticipants were randomized according to a balanced 3 × 3 Latin-square with 6 treatment sequences. in order to keep the balance of treatment sequences within each 
block, the identical block-randomization schedule was used for all three categories of the drug treatment (eg, MAS XR 10 mg/day, LDX 30 mg/day, and placebo; or MAS XR 
20 mg/day, LDX 50 mg/day, and placebo; or MAS XR 40 mg/day, LDX 70 mg/day, and placebo).
Abbreviations: LDX, lisdexamfetamine dimesylate; MAs Xr, mixed amphetamine salts extended release.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
270
López et al
comparisons. Frequencies of CGI-I were also assessed by 
McNemar test, a statistical method that can be used to ana-
lyze differences in response, when participants serve as their 
own controls or when participants are matched pairs. This 
test was used to compare participants’ responses to LDX and 
MAS XR on CGI-I scores dichotomized into 1 (very much 
improved) vs all other response scores (2 to 7) in a 2 × 2 
table. A P-value can be determined based on the numbers 
of discordant pairs, in this case, the number of participants 
whose CGI-I scores were different after treatment with LDX 
or MAS XR. Data from the crossover phase were analyzed 
independently of the dose administered and reflect the dose 
to which each participant was optimized to MAS XR in the 
crossover phase of the study.
Results
Study demographics, baseline characteristics, participant dis-
position, and primary results have been previously reported.5 
On the primary efficacy measure, SKAMP-D, participants 
receiving LDX and MAS XR had lower (better) LS mean 
(SE) SKAMP-D scores at endpoint of 0.8 (0.1) and 0.8 (0.1), 
respectively, in each comparison with placebo, 1.7 (0.1) 
(P , 0.0001 for each).
cgi-i
A total of 52 children (aged 6 to 12 years) were enrolled, 
titrated, and randomized; 50 completed the study postran-
domization. Physician rating of the participant’s overall clini-
cal improvement during the study using the CGI-I measure 
showed significant clinical improvement for participants who 
received LDX or MAS XR. The LS mean (SE) score was 
significantly better for the LDX-treated group (2.2 [0.2]) 
and for the MAS XR group (2.3 [0.2]) than for the placebo 
group (4.2 [0.2]) (P , 0.0001). Of the 50 ITT participants, 
32% were considered very much improved and 42% much 
improved in the LDX-treated group, as demonstrated by 
investigator-rated CGI-I scores at endpoint (Table 1). The 
investigators rated 74% of participants on LDX as either very 
much improved or much improved (32% very much improved 
and 42% much improved) on the CGI-I scale, compared with 
72% (16% very much improved and 56% much improved) of 
participants when they received MAS XR and 18% (2% very 
much improved and 16% much improved) of participants 
when they received placebo (Table 1).   Percentages of 
children rated very much improved after treatment included 
32% of the 50 children treated with LDX; 16% of these 
same 50 participants after treatment with MAS XR; and 
2% of placebo-treated participants (Table 1). Specifically, 
10 participants were rated very much improved with LDX, 
but not MAS XR, while 2 participants were rated very much 
improved with MAS XR, but not LDX (Table 2). Also, 6 
participants were rated very much improved with both LDX 
and MAS XR (Table 2). The McNemar test on the 2 × 2 table 
showed that LDX resulted in a significantly higher propor-
tion of participants with a very much improved score on the 
CGI-I than did MAS XR (P = 0.0386) (Table 2).
Overall, 42 participants in the crossover study were not 
very much improved when treated with MAS XR, of which 
10 were very much improved with LDX, but not MAS XR. 
Of these 10 participants, 3 received LDX at an earlier visit 
than MAS XR; and 7 received MAS XR at an earlier visit than 
LDX. Also, of the 34 participants who were not very much 
improved with LDX treatment, 2 were very much improved 
when treated with MAS XR, but not LDX. Both participants 
were treated with LDX at an earlier visit than MAS XR.
safety assessment
Safety results have previously been reported in detail.5 
Briefly, safety analysis indicated that no serious AEs were 
reported throughout the study. During the titration period 
Table 1 CGI-I scores at endpoint, ITT population, n (%)
Improved 
(CGI-I score = 2)
Very much improved 
(CGI-I score = 1)
LDX 37 (74) 16 (32)
MAs Xr 36 (72) 8 (16)
Placebo 9 (18) 1 (2)
Notes: cgi-i score of 1 = very much improved; cgi-i score of 2 = much improved.
Abbreviations:  cgi-i,  clinical  global  impressions-improvement;  iTT,  intention-
to-treat;  LDX,  lisdexamfetamine  dimesylate;  MAs  Xr,  mixed  amphetamine  salts 
extended release.
Table 2 Frequencies of cgi-i very much improveda vs otherb 
scores
LDX, n
All others Very much 
improved
Total
MAs Xr, n All others 32 10 42 (84.0%)
Very much 
improved
2 6 8 (16.0%)
Total 34 (68.0%) 16 (32.0%) 50
McNemar testc P = 0.0386
Notes: acgi-i very much improved score = 1; bcgi-i all other scores = 2, 3, 4, 5, 6, 
or 7; cMcNemar test is a test of agreement of participants’ responses to MAs Xr and 
LDX and is not a direct test on the percentages displayed in the table. 
Abbreviations:  cgi-i,  clinical  global  impressions-improvement;  LDX,  lisdex-
amfetamine dimesylate; MAs Xr, mixed amphetamine salts extended release.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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with MAS XR, 46% of participants reported an AE. The 
most common AEs were headache (15%), decreased appetite 
(14%), insomnia (10%), abdominal pain (6%), and upper 
abdominal pain (6%). During the double-blind phase, 16% of 
participants treated with LDX reported AEs compared with 
18% of those treated with MAS XR and 15% of those in the 
placebo group. The most common AEs associated with LDX 
treatment were insomnia (8%), decreased appetite (6%), and 
anorexia (4%); with MAS XR, upper abdominal pain (4%) 
and decreased appetite (4%); and placebo, vomiting (4%). 
No clinically meaningful vital sign or ECG findings were 
reported in patients treated with LDX or MAS XR.
Discussion
This clinical trial assessed the effect of LDX throughout the 
day in children with ADHD in a classroom setting compared 
with placebo and MAS XR. In general, the primary efficacy 
measure, SKAMP-D, indicated that treatment with either 
LDX or MAS XR is associated with improvement in ADHD 
symptoms and behavior, compared with placebo. This was 
demonstrated by a decrease in score, which is indicative 
of improvement in participant impairment in classroom 
behavior as assessed by an independent observer. Post hoc 
analysis of the data from this trial indicated a statistically 
significant difference between LDX and MAS XR treatment 
when examining the likelihood of being very much improved 
(CGI-I score = 1) when treated with LDX compared with 
MAS XR. Treatment with LDX resulted in a significantly 
higher number of participants who had a very much improved 
score on the CGI-I than with MAS XR, suggesting that 
the extent of improvement was greater with LDX. Thus, 
CGI-I assessment suggested that LDX treatment, given 
at doses containing approximately equivalent amounts of 
d-amphetamine as MAS XR, resulted in greater improvement 
in ADHD symptoms as indicated by a higher number of very 
much improved scores relative to comparators. Whereas 
many factors may have contributed to the differential find-
ings of similar efficacy on the SKAMP-D between LDX and 
MAS XR, and although LDX showed greater likelihood of 
very much improved scores, differences in timing of the 
assessments (repeatedly over 12 hours vs once during the 
analog classroom day) and the scope of assessments (specific 
measures of deportment vs global assessments of efficacy 
and tolerability) may have played a role.
Differences between LDX and MAS XR were observed 
using other secondary measures in this trial. Participants at 
12 hours postdose receiving LDX had significantly higher 
scores on the PERMP-A (math problems attempted) and 
PERMP-C (math problems correct) compared with children 
treated with MAS XR in a post hoc analysis, but not at the ear-
lier time points.10,11 These data indicate overall improvement 
in symptoms of ADHD in children relative to placebo with 
various outcome measures. As previously reported, at 12 hours 
postdose, SKAMP-D and SKAMP-A assessments indicated 
significant improvement in scores of participants treated 
with LDX relative to placebo. In a more recent,   double-blind, 
placebo-controlled, laboratory school study of children with 
ADHD, while no comparator arm of MAS XR was included, 
behavior and math test performance in participants receiving 
LDX showed significant improvement compared with placebo 
from 1.5 to 13 hours postdose (last time point assessed).8 
Taken together these findings suggest that the beneficial effects 
of LDX extend into later hours of the day.8
It is possible that this observed difference in treatment 
response to LDX and MAS XR may be due to the differences 
in delivery systems. LDX is a prodrug that depends on enzy-
matic cleavage to yield active d-amphetamine and l-lysine.12 
MAS XR uses a microbead technology to provide 2 pulses 
of MAS with a pharmacokinetic profile equivalent to 2 equal 
doses of MAS taken 4 hours apart.13,14 On the other hand, it 
is unclear if the open-label treatment phase with MAS XR 
could have affected subjective assessments of improvement 
related to switching medications.
We are not aware of previous studies that have reported 
on the comparative results of the more stringent CGI-I very 
much improved rating. The findings of this subanalysis may 
be important because a rating of very much improved on the 
CGI-I may be indicative of a more robust treatment response 
in many participants. In fact, recent work by Goodman et al 
has shown a correlation between scores on the ADHD-RS-IV 
and the CGI-I.15
These results should be interpreted carefully, due to 
limitations of the post hoc analysis. A number of design 
features contribute to the limited ability to extrapolate the 
findings of this analysis. The parent study was designed as 
a noninferiority study as well as not being prospectively 
designed or powered to detect differences between the 
products. Moreover, there were no differences in primary 
endpoints in this study. The CGI scale is widely used and 
easily scored; however, findings of test-retest reliability 
and validity are mixed.16 For this trial, though, the lim-
ited number of raters scoring this measure and limited 
number of repeated assessments (once for each crossover 
period) eliminated some concerns over the reliability of Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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this   measure. This study had a small sample size, and, 
additionally, treatment sequence in this crossover study 
could conceivably have affected the results. In relation 
to this, while no apparent treatment sequence effect is 
discernible for those participants who responded to one 
but not the other active treatment, the numbers of partici-
pants who met these criteria were too few to analyze this 
  statistically. The results of this analysis should be viewed 
as an exploratory endeavor to identify interesting prelimi-
nary results that can be confirmed in other well-controlled 
clinical trials with preplanned endpoints controlling for all 
pairwise comparisons.
In conclusion, the results of this analysis showed that, 
overall, participants with global illness were improved by 
both active treatments and more participants taking LDX 
were very much improved compared with those receiving 
MAS XR and placebo. These findings should be considered 
preliminary in light of the limitations of the analysis.
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